Sanofi agrees to sell a 50% stake in Opella to CDR for €15bn, securing job promises. Discover the impact on France ...

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00.

The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...

Exscientia (EXAI) announced the advancement of two additional discovery programs within its collaboration with Sanofi (SNY), ...